

Special Issue

Advanced Research in Hypertrophic Cardiomyopathy

Message from the Guest Editors

This Special Issue will focus on everything new in the risk stratification and management of hypertrophic cardiomyopathy, addressing the following:

- New trends in the treatment of hypertrophic cardiomyopathy (HCM) and the role of myosin inhibitors;
- Advantages and disadvantages of traditional and new therapies for HCM: septal reduction therapy vs. myosin inhibitors;
- Risk of arrhythmias while on myosin inhibitors;
- Treatment on the horizon for hypertrophic cardiomyopathy beyond myosin inhibitors;
- Gene therapy for hypertrophic cardiomyopathy;
- Contemporary trends in the risk stratification of sudden cardiac death in HCM;
- New research on understanding the genetic nature of HCM, focusing on the management and follow up of patients with genetically positive/phenotypically negative HCM profiles.

Guest Editors

Dr. Said Alsidawi

Dr. Juan Farina

Dr. Celestino Sardu

Deadline for manuscript submissions

31 March 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/217199

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).